What Are Disparities in Healthcare?
For people living with multiple myeloma, disparities in healthcare can spell the difference between early diagnosis and early treatment. Understanding these preventable differences is key to bridging the gap toward achieving multiple myeloma health equity, especially in socially disadvantaged populations.
Several factors contribute to disparities in healthcare, such as:1
- Educational inequalities: Lack of education can make it difficult for a person to recognize symptoms and understand their treatment options.
- Poverty: For people experiencing poverty, healthcare takes a backseat to basic necessities. Financial hardships make it harder for people to consult a doctor and seek treatment, preventing timely diagnosis and early treatment.
- Individual and behavioral factors: Underlying health conditions can affect the disease's progression and how a person's body responds to treatment.
- Environmental threats: Constant exposure to toxins due to one's living conditions or profession can increase the risk of cancer, making treatment more complicated.
- Inadequate access to healthcare: Geographic challenges and limited access to healthcare hinder timely diagnosis and adequate treatment, advanced therapies, and clinical trials.
- Systemic racism: Racial disparity in the healthcare system leads to inequalities in treatment, fewer referrals for advanced care, and underrepresentation in research. This significantly impacts people of color and minorities.
- Mistrust of the healthcare system: Systemic bias, coupled with past negative experiences, results in reluctance to seek treatment and lower participation in trials.
This above graph shows that Black people, Hispanic people, American Indian or Alaskan Native people, and Native Hawaiian or Other Pacific Islanders in the U.S. tend to fare worse in overall healthcare than White Americans.2
A 2024 systematic literature review of 33 U.S. studies comprising over 410,000 patients found that when data are adjusted for key confounding factors — including socioeconomic status, treatment access, and disease characteristics — Black patients with multiple myeloma exhibit survival outcomes equal to or better than White patients. This finding demonstrates that the survival gap is not biologically inevitable, but it is largely driven by unequal access to care and treatment.3
“Health equity is achieved when every person has the opportunity to ‘attain his or her full health potential’ and no one is ‘disadvantaged from achieving this potential because of social position or other socially determined circumstances.’”
See the facts:
The graphs below show that African Americans and Hispanic Americans have a higher incidence of myeloma and higher mortality rates from the disease. In fact, mortality rates are about twice as high in Black people as in white people.4
Myeloma Incidence: By the Numbers
The following graphs from the SEER website provide an overview of myeloma incidence among different demographics. They also help contextualize the disparities in patients with multiple myeloma.
Rate of cases and deaths per 100,000 persons:
Rates of new cases per 100,000 persons by race and percentage of new cases by age group:
Death rate per 100,000 persons by race/ethnicity and sex, and percentage of deaths by age group:
Five-year relative survival rate after diagnosis:
Percentage of cases and five-year relative survival by stage at diagnosis:
Prevalence of myeloma compared to other cancers in the United States:
Take a second look
Delayed treatment and lack of access to appropriate treatment protocols result in poorer health outcomes for African Americans and Hispanics. However, emerging research shows that when access to treatment is equalized, Black patients can achieve survival outcomes comparable to or better than White patients — reinforcing that these disparities are preventable and addressable. 3
The Role of Primary Care in Reducing Disparities
A 2022 review published in The American Journal of Medicine (Mikhael, Bhutani, and Cole) highlights that the majority of patients diagnosed with multiple myeloma initially present to their primary care provider (PCP) — and that on average, patients visit their PCP three times before a hematology referral is made. The diagnostic interval (time from first presentation to diagnosis) averages roughly 100 days, and is twice as long when a patient first presents to a PCP versus a hematologist. Critically, a real-world analysis found that 62% of patients who experienced a diagnostic delay were African American.
Part of the challenge is that multiple myeloma symptoms — bone pain, fatigue, anemia, renal insufficiency — overlap with more common conditions like diabetes, arthritis, and chronic kidney disease, all of which are more prevalent in Black patients. This overlap can cause providers to attribute myeloma symptoms to comorbidities, prolonging the path to diagnosis. Black/African American patients also present with a greater number of pre-existing comorbidities at diagnosis, further compounding this risk.
The review recommends that when multiple myeloma is suspected, PCPs initiate a testing protocol that includes serum protein electrophoresis (SPEP), serum free light chain assay (sFLC), and serum immunofixation electrophoresis (sIFE). Together, SPEP and sFLC achieve 100% diagnostic sensitivity for multiple myeloma. Black/African American patients are less likely than White patients to receive this full diagnostic workup — a gap that contributes directly to the higher rates of delayed diagnosis in this population. Heightened awareness and consistent application of these diagnostic steps in high-risk populations is a concrete, actionable way to begin closing the disparity gap.5
Disparities in Medicare
Characteristics, Experiences and Outcomes of the Medicare Population by Race and Ethnicity
A February 2021 Kaiser Family Foundation (KFF) study on “Racial and Ethnic Health Inequities and Medicare” drew “primary and secondary data analyses by KFF and other sources to examine the characteristics, experiences, and outcomes of the Medicare population by race and ethnicity.”
Data from “a variety of sources to describe demographics, health status and disease prevalence, health coverage, access to care and service utilization and health outcomes, including the most current data available pertaining to disparities related to COVID-19 within the Medicare population” were collected for this purpose. The study also documents “disparities in income and wealth among people on Medicare.”
Key Takeaways
- Since the enactment of Medicare among all older adults, life expectancy at age 65 has improved. However, it is lower for Black adults than White or Hispanic adults (18.0, 19.4, and 21.4 years, respectively) and higher for Hispanic adults than Black or White adults.
- Compared to White Medicare beneficiaries, Black and Hispanic beneficiaries have “fewer years of formal education and lower median per capita income, savings, and home equity” overall.
- “Among Medicare beneficiaries, people of color are more likely to report being in relatively poor health, have higher prevalence rates of some chronic conditions, such as hypertension and diabetes than White beneficiaries; they are also less likely to have one or more doctor visit, but have higher rates of hospital admissions and emergency department visits than White beneficiaries.”
- “While the vast majority of Medicare beneficiaries across all racial and ethnic groups have some source of supplemental coverage to help fill in Medicare’s benefit gaps and cost-sharing requirements, the share of beneficiaries with different types of coverage varies by race and ethnicity. A smaller share of Black and Hispanic Medicare beneficiaries than White beneficiaries have private supplemental coverage through Medigap or retiree health plans, while a larger share have wrap-around coverage under Medicaid; a larger share of Black and Hispanic than White beneficiaries are enrolled in Medicare Advantage plans.”
- “While relatively few Medicare beneficiaries overall report problems with access to care, a larger share of Black and Hispanic beneficiaries report trouble getting needed care than White beneficiaries.”
- “The COVID-19 pandemic has further highlighted stark racial/ethnic health inequities among Medicare beneficiaries, with Black, Hispanic, and American Indian/Alaska Natives accounting for disproportionate rates of COVID-19 cases and hospitalizations. Among adults ages 65 and older, people of color bear disproportionate rates of COVID-19 deaths relative to older White adults.”
Disparities in Medicare Advantage Enrollees by Race and Ethnicity
A December 2023 KFF Report on “Disparities in Health Measures by Race and Ethnicity Among Beneficiaries in Medicare Advantage: A Review of the Literature” revealed that:
- Over 50 percent of all Medicare beneficiaries are enrolled in Medicare Advantage plans, “with higher enrollment rates among Black, Hispanic, and Asian and Pacific Islander beneficiaries” compared to White beneficiaries.
- As of 2021, enrollment in Medicare Advantage by racial groups are as follows: Blacks (59 percent); Hispanics (67 percent); Asian and Pacific Islanders (55 percent); and Whites (43 percent).
- The KFF review “examines differences in measures of quality of care and beneficiary experience between people of color in Medicare Advantage plans and White Medicare Advantage enrollees or the total Medicare Advantage population.”
- Findings from 20 identified published studies (published during a 5-year period, between January 2018 and April 2023) were synthesized in the analysis.
- The 20 studies “collectively report on 46 different measures of quality of care and beneficiary experience, but not all studies examined all groups or included all measures.”
- 17 of the 20 studies are controlled “for differences in enrollee health status and other demographic characteristics in some fashion.”
- “While the scope of this review is limited to Medicare Advantage enrollees, the racial and ethnic disparities in quality of care and beneficiary described in this report mirror disparities in health and health care in traditional Medicare, the overall Medicare population, and more broadly, the U.S adult population.”
BIPOC and Access to Healthcare
A 2023 study by Kaiser Family Foundation on Key Data on Health and Health Care by Race and Ethnicity discuss how “racial and ethnic disparities in health and healthcare remain a persistent challenge in the United States."
The COVID-19 pandemic has made inequities in health and healthcare for people of color more pronounced. However, “they have been documented for decades and reflect longstanding structural and systemic inequities rooted in racism and discrimination."
Social determinants of health also play a major role when it comes to inequities “across broader social and economic factors that drive health.”
The analysis examines how people of color across “a broad range of measures of health, healthcare, and social determinants of health compared to whites. Data is presented for six groups, where necessary: White, Asian, Hispanic, African American, American Indian and Alaska Native (AIAN), and Native Hawaiian and Other Pacific Islander (NHOPI).
1.“Health Disparities.” Centers for Disease Control and Prevention, November 24, 2020. https://www.cdc.gov/healthyyouth/disparities/index.htm#1
2. Hill, L., Artiga, S., and Halder, S. “Key Facts on Health and Health Care by Race and Ethnicity.” Kaiser Family Foundation, March 15, 2023. https://www.kff.org/racial-equity-and-health-policy/report/key-facts-on-health-and-health-care-by-race-and-ethnicity/
3. Mikhael, Joseph et al. “Overall Survival in Patients With Multiple Myeloma in the U.S.: A Systematic Literature Review of Racial Disparities.” Clinical lymphoma, myeloma & leukemia vol. 24,2 (2024): e1-e12. doi:10.1016/j.clml.2023.09.009
4. “Cancer Stat Facts: Myeloma.” Surveillance, Epidemiology, and End Results Program, National Cancer Institute, 2025, https://seer.cancer.gov/statfacts/html/mulmy.html
5. Mikhael J, Bhutani M, Cole C. "Multiple Myeloma for the Primary Care Provider: A Practical Review to Promote Earlier Diagnosis Among Diverse Populations." The American Journal of Medicine, 2022; 136, 33-41. DOI: 10.1016/j.amjmed.2022.08.030
6. Salafian, Kiarash et al. “The impact of social vulnerability index on survival following autologous stem cell transplant for multiple myeloma.” Bone Marrow Transplantation, January 18, 2024, https://www.nature.com/articles/s41409-024-02200-x
Support Our Cause
Join our campaign against healthcare disparities for people living with multiple myeloma. Connect with our team to learn how you can contribute to the IMF's goals of making healthcare accessible.
With support from:
AbbVie, Amgen, Bristol Myers Squibb, Genentech , GSK, Johnson & Johnson, Karyopharm Therapeutics, Kite, and Sanofi
The International Myeloma Foundation medical and editorial content team
Comprised of leading medical researchers, hematologists, oncologists, oncology-certified nurses, medical editors, and medical journalists, our team has extensive knowledge of the multiple myeloma treatment and care landscape.
Additionally, the content on this page is medically reviewed by myeloma physicians and healthcare professionals.
Last medical content review: April 14, 2026
Explore the IMF's M-Power Project. Partnered with cities across the U.S., this project aims to eliminate health disparities and create better and more equitable access to healthcare for all.




